ENLIVEX THERAPEUTICS LTD (ENLV) Stock Price, Forecast & Analysis
USA - NASDAQ:ENLV - IL0011319527 - Common Stock
ENLV Key Statistics, Chart & Performance
The current stock price of ENLV is 1.05 USD. In the past month the price decreased by -0.94%. In the past year, price decreased by -22.79%.
ENLV Latest News, Press Relases and Analysis
ENLV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About ENLV
Company Profile
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Company Info
ENLIVEX THERAPEUTICS LTD
14 Einstein St.
Ness Ziona 7403618 IL
CEO: Oren Hershkovitz
Employees: 36
Phone: 97286623301
ENLIVEX THERAPEUTICS LTD / ENLV FAQ
What does ENLV do?
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
What is the stock price of ENLIVEX THERAPEUTICS LTD today?
The current stock price of ENLV is 1.05 USD.
Does ENLIVEX THERAPEUTICS LTD pay dividends?
ENLV does not pay a dividend.
How is the ChartMill rating for ENLIVEX THERAPEUTICS LTD?
ENLV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of ENLV stock?
ENLIVEX THERAPEUTICS LTD (ENLV) has a market capitalization of 25.50M USD. This makes ENLV a Nano Cap stock.
What is the ownership structure of ENLIVEX THERAPEUTICS LTD (ENLV)?
You can find the ownership structure of ENLIVEX THERAPEUTICS LTD (ENLV) on the Ownership tab.
Can you provide the short interest for ENLV stock?
The outstanding short interest for ENLIVEX THERAPEUTICS LTD (ENLV) is 0.75% of its float.
ENLV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ENLV. When comparing the yearly performance of all stocks, ENLV is a bad performer in the overall market: 90.75% of all stocks are doing better.
ENLV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENLV. The financial health of ENLV is average, but there are quite some concerns on its profitability.
ENLV Financial Highlights
Over the last trailing twelve months ENLV reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 50.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.96% | ||
| ROE | -68.74% | ||
| Debt/Equity | 0 |
ENLV Forecast & Estimates
8 analysts have analysed ENLV and the average price target is 10.2 USD. This implies a price increase of 871.43% is expected in the next year compared to the current price of 1.05.